Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 25c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $6.64, $0.25 better than the analyst estimate of $6.39. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.16 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Dell’s earning report was bullish for Intel CPU demand, analyst says
• TransUnion (TRU) call put ratio 1 call to 4.2 puts with a focus on January 47.50 puts as share price down 9.5%
• Honda Motor names Mamadou Diallo as Auto Business Center EVP